GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lexagene Holdings Inc (OTCPK:LXXGQ) » Definitions » Cyclically Adjusted PS Ratio

Lexagene Holdings (Lexagene Holdings) Cyclically Adjusted PS Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Lexagene Holdings Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lexagene Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Lexagene Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexagene Holdings Cyclically Adjusted PS Ratio Chart

Lexagene Holdings Annual Data
Trend Mar13 Mar14 Mar15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 280.00 -

Lexagene Holdings Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 114.26 - - 43.47 -

Competitive Comparison of Lexagene Holdings's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Lexagene Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexagene Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lexagene Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lexagene Holdings's Cyclically Adjusted PS Ratio falls into.



Lexagene Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Lexagene Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Nov. 2022 is calculated as:

For example, Lexagene Holdings's adjusted Revenue per Share data for the three months ended in Nov. 2022 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Nov. 2022 (Change)*Current CPI (Nov. 2022)
=0/125.6074*125.6074
=0.000

Current CPI (Nov. 2022) = 125.6074.

Lexagene Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201212 0.000 96.871 0.000
201303 0.000 98.209 0.000
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201702 0.000 102.779 0.000
201705 0.000 103.256 0.000
201708 0.000 103.587 0.000
201711 0.000 104.072 0.000
201802 0.000 105.052 0.000
201805 0.000 106.148 0.000
201808 0.000 106.383 0.000
201811 0.000 106.338 0.000
201902 0.000 106.649 0.000
201905 0.000 108.048 0.000
201908 0.000 108.245 0.000
201911 0.000 108.519 0.000
202002 0.000 109.139 0.000
202005 0.000 108.175 0.000
202008 0.000 109.662 0.000
202011 0.000 109.793 0.000
202102 0.001 110.968 0.001
202105 0.000 113.576 0.000
202108 0.000 115.421 0.000
202111 0.000 117.269 0.000
202202 0.000 119.703 0.000
202205 0.000 123.323 0.000
202208 0.000 124.958 0.000
202211 0.000 125.607 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lexagene Holdings  (OTCPK:LXXGQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Lexagene Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Lexagene Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexagene Holdings (Lexagene Holdings) Business Description

Traded in Other Exchanges
N/A
Address
500 Cummings Center, Suite 4550, Beverly, MA, USA, 01915
Lexagene Holdings Inc is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The MiQLab system delivers sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.